Arbli™ Oral Suspension Manufacturing Readiness Announced
TAMPA, FL – SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) is excited to share that its subsidiary, Scienture, LLC, has commenced its supply chain operations to produce Arbli™ (losartan potassium) Oral Suspension at a concentration of 10 mg/mL. The team anticipates launching this novel product by July 2025, aiming to provide a valuable alternative in the treatment of hypertension.
The Significance of Arbli™ in Hypertension Treatment
Arbli™ is tailored for individuals aged 6 and older, designed specifically for hypertension treatment. It plays a critical role in not just lowering blood pressure but also reducing the risk of strokes among patients facing hypertension, particularly those with left ventricular hypertrophy, and managing diabetic nephropathy in specific cases of type 2 diabetes. This product stands out as the first FDA-approved ready-to-use oral liquid formulation of losartan available in the United States.
Innovative Features of Arbli™
What makes Arbli™ unique is its proprietary formulation that simplifies dosing for those who may require or prefer a liquid form of losartan. This innovation eliminates the need for compounding, which can lead to inconsistencies when tablets are crushed for liquid preparation. Being an FDA-approved product ensures not only safety but also provides patients and caregivers with confidence in medication quality and efficacy.
Market Impact
The potential for Arbli™ to introduce a game-changing option in the market is underscored by current IQVIA data, which indicates that losartan products have amassed approximately $292 million in annual sales, with around 68 million prescriptions dispensed in the U.S. This clearly illustrates the necessity for alternatives like Arbli™, which meet the evolving needs of patients.
Readiness for Market Launch
The confidence in the ability to launch on time stems from the established production capabilities of Saptalis Pharmaceuticals, LLC, a partner of Scienture, which is equipped to deliver batch quantities well in advance of the commercial release. Additionally, plans for adequate warehousing and distribution to various wholesalers are already in place, allowing for seamless market entry.
Leadership Insights
Narasimhan Mani, President of Scienture, LLC, commented on the achievement of manufacturing readiness, stating, "Our progress in launching Arbli™ reflects the dedication of our teams and our strong infrastructure partnerships. We are prepared to ensure timely access for patients who require this innovative treatment." Shankar Hariharan, the CEO of Scienture, added, "Our commitment to quality and patient safety is evident in our robust supply chain and technical processes. This milestone marks an important step towards providing therapeutic options that fulfill market needs."
What Makes Arbli™ Distinctive?
Arbli™ not only comes in a user-friendly 165 mL bottle with a peppermint flavor but also has a commendable shelf life of 18 months when stored at room temperature—an aspect that enhances its usability. Plans are underway to extend this stability up to 24 months upon further testing and submission of new stability data to the FDA.
Indications and Safety Information
The FDA labels Arbli™ as an angiotensin II receptor blocker (ARB), vital for treating hypertension in adults and children. It reduces the likelihood of severe cardiovascular issues and is essential for patients with diabetic nephropathy. Importantly, patients must adhere to safety guidelines, including avoiding Arbli™ during pregnancy due to potential fetal harm.
Understanding Hypertension
Hypertension, often termed high blood pressure, affects nearly half of the adult population in the U.S. It increases the risk of life-threatening conditions like strokes and heart disease. With factors such as age, obesity, and lifestyle playing roles in its prevalence, effective treatments like Arbli™ are critical for healthcare providers managing these risks.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) operates through its subsidiary, Scienture, LLC, focusing on developing unique specialty pharmaceutical products. With a commitment to enhancing patient and healthcare system value, Scienture is set to grow its portfolio in various therapeutic areas.
Frequently Asked Questions
What is Arbli™ and its main use?
Arbli™ is an FDA-approved oral suspension for treating hypertension in patients over 6 years old, pivotal for reducing stroke risks and managing diabetic nephropathy.
Why is Arbli™ important in hypertension treatment?
It provides a liquid formulation option for patients who need or prefer non-solid forms of medication, making dosing easier and safer.
When is the expected launch of Arbli™?
The anticipated launch date for Arbli™ is July 2025.
Who is involved in the manufacturing of Arbli™?
Saptalis Pharmaceuticals, LLC is the contract manufacturing partner tasked with producing Arbli™'s batches for market launch.
How does Scienture ensure safety and quality?
Scienture maintains rigorous compliance with manufacturing standards and safety protocols to ensure the quality of Arbli™ for patients.
